© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 15, 1153-1158,
August 1, 2001
© 2001 Oxford University Press
REPORT |
Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval
Affiliations of authors: R. F. Hoedemaeker, T. H. van der Kwast, A. N. Vis (Department of Pathology), R. Boer, H. J. de Koning (Department of Public Health), M. Roobol, F. H. Schröder (Department of Urology), Erasmus University Rotterdam, The Netherlands.
Correspondence to: Robert F. Hoedemaeker, M.D., Department of Pathology, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands (e-mail: Hoedemaeker{at}path.fgg.eur.nl).
Background: The currently recommended frequency for prostate-specific antigen (PSA) screening tests for prostate cancer is 1 year, but the optimal screening interval is not known. Our goal was to determine if a longer interval would compromise the detection of curable prostate cancer. Methods: A cohort of 4491 men aged 55–75 years, all participants in the Rotterdam section of the European Randomized Study of (population-based) Screening for Prostate Cancer, were invited to participate in an initial PSA screening. Men who received that screening were invited for a second screen 4 years later. Pathology findings from needle biopsy cores were compared for men in both rounds. Statistical tests were two-sided. Results: A total of 4133 men were screened in the first round (the prevalence screen), and 2385 were screened in the second round. The median amount of cancer in needle biopsy sets was 7.0 mm (95% confidence interval [CI] = 5.4 mm to 8.6 mm) in the first round and 4.1 mm (95% CI = 2.6 mm to 5.6 mm) in the second round (P = .001). Thirty-six percent of the adenocarcinomas detected in the first round but only 16% of those detected in the second round had a Gleason score of 7 or higher (mean difference = 20% [95% CI = 10% to 30%]; P<.001). Whereas 25% of the adenocarcinomas detected in the first round had adverse prognostic features, only 6% of those detected in the second round did (mean difference = 19% [95% CI = 11% to 26%]; P<.001). Baseline PSA values were predictive for the amount of tumor in biopsies in men with cancer in the first round but not for that in the second round. Conclusion: Most large prostate cancers with high serum PSA levels were effectively detected in a prevalence screen. In this population, a screening interval of 4 years appears to be short enough to constrain the development of large tumors, although it is inconclusive whether this will result in a survival benefit.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Y. Lotan, J. A. Cadeddu, J. J. Lee, C. G. Roehrborn, and S. M. Lippman Implications of the Prostate Cancer Prevention Trial: A Decision Analysis Model of Survival Outcomes J. Clin. Oncol., March 20, 2005; 23(9): 1911 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Andriole, D. L. Levin, E. D. Crawford, E. P. Gelmann, P. F. Pinsky, D. Chia, B. S. Kramer, D. Reding, T. R. Church, R. L. Grubb, et al. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial J Natl Cancer Inst, March 16, 2005; 97(6): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Makinen, T. L. J. Tammela, U.-H. Stenman, L. Maattanen, J. Aro, H. Juusela, P. Martikainen, M. Hakama, and A. Auvinen Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial Clin. Cancer Res., April 1, 2004; 10(7): 2231 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Scardino The Prevention of Prostate Cancer -- The Dilemma Continues N. Engl. J. Med., July 17, 2003; 349(3): 297 - 299. [Full Text] [PDF]
|
|
|
|
|
|
T. Makinen, T. L. J. Tammela, M. Hakama, U.-H. Stenman, S. Rannikko, J. Aro, H. Juusela, L. Maattanen, and A. Auvinen Tumor Characteristics in a Population-based Prostate Cancer Screening Trial with Prostate-specific Antigen Clin. Cancer Res., July 1, 2003; 9(7): 2435 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. H van der Kwast, C Lopes, C Santonja, C-G Pihl, I Neetens, P Martikainen, S Di Lollo, L Bubendorf, and R F Hoedemaeker Guidelines for processing and reporting of prostatic needle biopsies J. Clin. Pathol., May 1, 2003; 56(5): 336 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Harris and K. N. Lohr Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, December 3, 2002; 137(11): 917 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Stamey Re: Pathologic Features of Prostate Cancer Found at Population-Based Screening With a Four-Year Interval J Natl Cancer Inst, February 6, 2002; 94(3): 227 - 228. [Full Text] [PDF]
|
|